publication of results of two large clinical trials: for patients in good general condition and for patients in performance status 2. Studies open a new perspective, in particular regarding chemotherapy with low-dose gemcitabine
F.02 Acquisition of new scientific knowledge
COBISS.SI-ID: 805243Invited lecture at an international conference
B.04 Guest lecture
COBISS.SI-ID: 785531Introduction of a new combination of treatment, based on differences in cell kinetics between chemotherapy and targeted drugs. Theoretical considerations and preliminary clinical experience indicate that this approach may have great impact for our future treatment of patients with lung adenocarcinoma positive for EGFR activating mutations
F.02 Acquisition of new scientific knowledge
COBISS.SI-ID: 1013115In a prospective clinical trial for patients with mesothelioma, low-dose gemcitabine in long infusion in combination with cisplatin proved to be an effective and safe treatment. Median survival of 17 months compares favourably with majority of other clinical trials. For comparison: combination of pemetrexed and cisplatin leads to median survival of 12 months; the costs for pemetrexed are at least 20 fold higher. Our original combination offers a new effective combination to the spectrum of treatments for mesothelioma
F.02 Acquisition of new scientific knowledge
COBISS.SI-ID: 00000000